TY  - JOUR
AU  - Pinyol, Roser
AU  - Montal, Robert
AU  - Bassaganyas, Laia
AU  - Sia, Daniela
AU  - Takayama, Tadatoshi
AU  - Chau, Gar-Yang
AU  - Mazzaferro, Vincenzo
AU  - Roayaie, Sasan
AU  - Lee, Han Chu
AU  - Kokudo, Norihiro
AU  - Zhang, Zhongyang
AU  - Torrecilla, Sara
AU  - Moeini, Agrin
AU  - Rodriguez-Carunchio, Leonardo
AU  - Gane, Edward
AU  - Verslype, Chris
AU  - Croitoru, Adina Emilia
AU  - Cillo, Umberto
AU  - de la Mata, Manuel
AU  - Lupo, Luigi
AU  - Strasser, Simone
AU  - Park, Joong-Won
AU  - Camps, Jordi
AU  - Sole, Manel
AU  - Thung, Swan N
AU  - Villanueva, Augusto
AU  - Pena, Carol
AU  - Meinhardt, Gerold
AU  - Bruix, Jordi
AU  - Llovet, Josep M
PY  - 2018
DO  - 10.1136/gutjnl-2018-316408
UR  - http://hdl.handle.net/10668/12835
T2  - Gut
AB  - Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with...
LA  - en
PB  - BMJ Group
KW  - Cancer
KW  - Clinical trials
KW  - Hepatocellular carcinoma
KW  - Molecular oncology
KW  - Tumour markers
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiogenesis inhibitors
KW  - Biopsy, needle
KW  - Carcinoma, hepatocellular
KW  - Chemotherapy, adjuvant
KW  - Disease-free survival
KW  - Female
KW  - Humans
KW  - Immunohistochemistry
KW  - Liver neoplasms
KW  - Male
KW  - Middle aged
KW  - Molecular targeted therapy
KW  - Neoplasm invasiveness
KW  - Neoplasm recurrence, local
KW  - Neoplasm staging
KW  - Predictive value of tests
KW  - Prognosis
KW  - Sorafenib
TI  - Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
TY  - research article
VL  - 68
ER  -